Relationship between Baseline Clinical Characteristics and CD4+ T Cell Count Recovery as well as Immune Reconstitution in AIDS Patients Treated with Antiretroviral Therapy
-
摘要:
目的 探讨艾滋病抗病毒治疗患者基线临床特征与CD4+T细胞计数恢复及免疫重建的关系分析。 方法 纳入2018年1月至2021年1月桂林市中医医院166例HIV患者,收集基线资料,根据世界卫生组织(WHO)指南,CD4+ T细胞计数较基线增加 > 50个/μL定义为CD4+ T细胞计数恢复,CD4+ T细胞计数≥500个/μL定义为免疫重建。分析ART期间的生存率、CD4+ T细胞计数恢复和免疫重建模式,并确定与ART结局相关的基线特征。 结果 ART 3、12、36个月艾滋病相关累计病死率分别为3.0%、3.6%、5.4%;CD4+T细胞恢复率分别为62.7%、80.7%、89.2%;基线CD4+ T细胞 < 500 cells/μL的145例患者36个月免疫重建率为65.5%。临床Ⅳ期和基线CD4≤200 cells/μL患者生存率较低。基线CD4预测3、12、36个月免疫重建的AUC分别为0.807、0.777、0.772,截断值分别为352、318、295 cells/μL;多因素分析显示临床Ⅳ期(OR = 0.22)和CD4 < 200 cells/μL(OR = 0.15)是36个月免疫重建的独立危险因素。 结论 HIV感染治疗前临床分期较晚、外周血CD4+ T细胞计数低以及ART启动前病毒载量高,是HIV/AIDS患者生存、CD4+ T细胞计数恢复和免疫重建的预测因素。 Abstract:Objective To investigate the association between baseline clinical characteristics and CD4+ T-cell count recovery and immune reconstitution in patients with HIV/AIDS receiving antiretroviral therapy (ART). Methods A total of 166 patients with HIV/AIDS who initiated ART at Guilin Traditional Chinese Medicine Hospital between January 2018 and January 2021 were enrolled, and baseline data were collected. CD4+ T-cell count recovery was defined as an increase of > 50 cells/μL from baseline. For patients with baseline CD4+ T-cell counts < 500 cells/μL, immune reconstitution was defined as achieving a CD4+ T-cell count ≥500 cells/μL. Survival rates, CD4+ T-cell count recovery, and immune reconstitution patterns during ART were analyzed, and baseline characteristics associated with ART outcomes were identified. Results The cumulative AIDS-related mortality rates at 3, 12, and 36 months after ART initiation were 3.0%, 3.6%, and 5.4%, respectively; The CD4+ T-cell count recovery rates were 62.7%, 80.7%, and 89.2%, respectively. Among the 145 patients with baseline CD4+ T-cell count < 500 cells/μL, the 36-month immune reconstitution rate was 65.5%. Patients with clinical stage IV disease and baseline CD4+ T-cell count ≤200 cells/μL had lower survival rates. Baseline CD4+ T-cell count predicted immune reconstitution at 3, 12, and 36 months, with areas under the receiver operating characteristic curve (AUCs) of 0.807, 0.777, and 0.772 and cutoff values of 352, 318, and 295 cells/μL, respectively. In multivariable logistic regression analysis, clinical stage IV disease (OR = 0.22) and baseline CD4+ T-cell count < 200 cells/μL (OR = 0.15) were independent risk factors for failure to achieve immune reconstitution at 36 months. Conclusion Advanced clinical stage before treatment, low baseline peripheral blood CD4+ T-cell count, and high viral load before ART initiation are predictors of survival, CD4+ T-cell count recovery, and immune reconstitution in patients with HIV/AIDS. -
表 1 HIV患者的人口统计学和临床特征
Table 1. Demographic and clinical characteristics of HIV patients
项目 男(n = 130) 女(n = 36) 总数 年龄/岁 31.8 ± 8.4 33.6 ± 10.3 32.20 ± 8.9 性行为 异性恋 22/13.2 28/16.9 50/30.1 同性恋 83/50.0 10/6.02 93/56.0 双性恋 25/15.1 2/1.20 27/16.3 临床分期 Ⅰ期 75/45.2 26/15.7 101/60.8 Ⅱ期 7/4.2 2/1.2 9/5.4 Ⅲ期 16/9.6 2/1.2 18/10.8 Ⅳ期 32/19.3 6/3.6 38/22.9 ART前的CD4+ T
细胞计数( cells/μL)317.8 ± 154.1 364.5 ± 183.7 327.9 ± 161.6 < 200 34/20.5 7/4.2 41/24.7 201~350 41/24.7 9/5.4 50/30.1 351~500 42/25.3 12/7.2 54/32.5 > 500 13/7.8 8/4.8 21/12.7 基线病毒载量
(拷贝数/mL)高( > 100000 )37/33.3 8/7.2 45/40.5 中( 10001 -100000 )30/27.0 9/8.1 39/35.1 低(≤ 10000 )18/16.2 9/8.1 27/24.3 ART方案 TDF+3TC+EFV 109/65.7 26/15.7 135/81.3 TDF+FTC+EFV 21/12.7 10/6.0 31/18.7 ART:抗逆转录病毒;3TC:拉米夫定;抗逆转录病毒治疗;EFV:依非韦伦;FTC:恩曲他滨;TDF:替诺福韦;WHO: 世界卫生组织(仅用于临床分期)。 表 2 接受ART 治疗的患者的生存率、CD4+ T细胞计数恢复和免疫重建
Table 2. Survival Rates,CD4+ T-Cell Count Recovery,and Immune Reconstitution in Patients Receiving ART
生存、CD4 恢复和免疫重建 例,%,(分子/分母) 入组患者 (166,100%) 166/166 抗逆转录病毒治疗36个月
艾滋病相关累计病死率(9,5.4%)9/166 抗逆转录病毒治疗12个月
的艾滋病相关累计病死率(6,3.6%)6/166 抗逆转录病毒治疗3个月
的艾滋病相关累计病死率(5,3.0%)5/166 ART期间CD4+ T细胞计数
恢复(增加 > 50个 cells/μL)3个月内恢复 (104,62.7%)104/166 12个月内恢复 (134,80.7%)134/166 36个月内恢复 (148,89.2%)148/166 免疫重建分析集(基线CD4+ T
细胞计数 < 500 cells/μL)145/166(87.3) ART开始前以正常速率
( > 500 cells/μL)(21,12.7%)21/145 3个月内重建 (42,29.0%)42/145 12个月内重建 (69,47.6%)69/145 36个月内重建 (95,65.5%)95/145 抗逆转录病毒治疗期间无重建 (50,34.5%)50/145 表 3 生存率与基线特征的相关性
Table 3. Correlation between survival rate and baseline characteristics
基线特征# 死亡组 生存组 临床分期 Ⅰ-Ⅲ期 0 128 Ⅳ期 9 29 CD4+ T细胞计数(cells/μL) < 200 9 32 ≥200 0 125 病毒载量&(拷贝/毫升) ≥ 500000 3 13 < 500000 3 92 缩写:因死亡例数过少(n = 9),仅作描述性分析,未进行统计学检验。 表 4 CD4+ T细胞计数恢复与基线特征的相关性
Table 4. Correlation between CD4+ T cell count recovery and baseline characteristics
基线特征# 恢复无响应组 恢复组 P 临床分期 Ⅰ-Ⅲ期 8 120 < 0.001* Ⅳ期 10 28 CD4+ T细胞计数(cells/μL) < 200 10 31 < 0.001* ≥200 8 117 *Fisher精确检验。恢复定义为CD4+ T细胞计数较基线增加 > 50 cells/μL。 表 5 免疫重建与基线特征的相关性
Table 5. Correlation between immune reconstitution and baseline characteristics
基线特征 3个月免疫重建率[n(%)] 12个月免疫重建率[n(%)] 36个月免疫重建率[n(%)] CD4+ T细胞计数(cells/μL) < 200 0(0/41)* 14.6(6/41)* 36.6(15/41)* 200~350 30.0(15/50) 52.0(26/50) 78.0(39/50) 351~500 50.0(27/54) 64.8(35/54) 75.9(41/54) 临床分期 Ⅰ期 30.2(26/86)* 61.6(53/86)* 74.4(64/86)* Ⅱ期 37.5(3/8) 50.0(4/8) 87.5(7/8) Ⅲ期 35.3(6/17) 58.8(10/17) 76.5(13/17) Ⅳ期 0(0/34) 14.7(5/34) 41.2(14/34) 病毒载量& ≥ 500000 copies/mL12.5(4/32)* 43.8(14/32) 62.5(20/32) < 500000 copies/mL37.9(25/66) 56.1(37/66) 69.7(46/66) 注:*P < 0.001。 表 6 36个月免疫重建的多因素Logistic回归分析
Table 6. Multivariate logistic regression analysis of immune reconstitution at 36 months
变量 调整OR (95%CI) P 临床Ⅳ期(vs Ⅰ-Ⅲ期) 0.22 (0.08–0.60) 0.003 基线CD4 < 200 cells/μL(vs ≥200) 0.15 (0.05–0.44) < 0.001* 病毒载量 ≥ 500000 copies/mL
(vs <500000 )0.58 (0.22–1.53) 0.275 表 7 不同基线CD4+ T细胞计数亚组的病毒抑制与免疫重建比较
Table 7. Comparison of viral suppression and immune reconstitution among subgroups with different baseline CD4+ T cell counts
项目 时间点 < 200 cells/μL
(n = 41)200~350 cells/μL
(n = 50)351~500 cells/μL
(n = 54)> 500 cells/μL
(n = 21)χ2值 P值 病毒抑制率 (%) 3个月 65.9 (27/41) 72.0 (36/50) 77.8 (42/54) 71.4 (15/21) 2.34 0.506 12个月 85.4 (35/41) 90.0 (45/50) 90.7 (49/54) 85.7 (18/21) 2.01 0.571 36个月 90.2 (37/41) 94.0 (47/50) 94.4 (51/54) 95.2 (20/21) 1.18 0.758 免疫重建率 (%)* 3个月 0 (0/41) 30.0 (15/50) 50.0 (27/54) - - < 0.001† 12个月 14.6 (6/41) 52.0 (26/50) 64.8 (35/54) - - < 0.001† 36个月 36.6 (15/41) 78.0 (39/50) 75.9 (41/54) - - < 0.001† *免疫重建率仅在基线CD4 < 500 cells/μL的145例患者中计算。†采用Fisher精确检验。病毒抑制率比较采用Pearson卡方检验。 -
[1] Cohn L B, Chomont N, Deeks S G. The biology of the HIV-1 latent reservoir and implications for cure strategies[J]. Cell Host Microbe, 2020, 27(4): 519-530. doi: 10.1016/j.chom.2020.03.014 [2] Lee S K, Sondgeroth A, Xu Y, et al. Sequence analysis of inducible, replication-competent virus reveals no evidence of HIV-1 evolution during suppressive antiviral therapy, indicating a lack of ongoing viral replication[J]. Open Forum Infect Dis, 2024, 11(5): ofae212. doi: 10.1093/ofid/ofae212 [3] Ward A R, Mota T M, Jones R B. Immunological approaches to HIV cure[J]. Semin Immunol, 2021, 51: 101412. doi: 10.1016/j.smim.2020.101412 [4] Espineira S, Flores-piñas M, Chafino S, et al. Multi-omics in HIV: searching insights to understand immunological non-response in PLHIV[J]. Front Immunol, 2023, 14: 1228795. doi: 10.3389/fimmu.2023.1228795 [5] Thomas J, Ruggiero A, Paxton W A, et al. Measuring the success of HIV-1 cure strategies[J]. Front Cell Infect Microbiol, 2020, 10: 134. doi: 10.3389/fcimb.2020.00134 [6] Tibúrcio R, Barreto-Duarte B, Naredren G, et al. Dynamics of T-lymphocyte activation related to paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome in persons with advanced HIV[J]. Front Immunol, 2021, 12: 757843. doi: 10.3389/fimmu.2021.757843 [7] Salles C, Cruz M M E, Freire I C, et al. Insomnia in older HIV-positive patients[J]. Sleep Sci, 2022, 15(3): 363-369. doi: 10.5935/1984-0063.20220064 [8] Katusiime M G, Neer V, Guo S, et al. Divergent populations of HIV-infected naive and memory CD4+ T cell clones in children on antiretroviral therapy[J]. J Clin Invest, 2025, 135(9): e188533. doi: 10.1172/JCI188533 [9] Ayrga S, Koorsen G. Metabolic reprogramming in HIV+ CD4+ T-cells: implications for immune dysfunction and therapeutic targets in M. tuberculosis co-infection[J]. Metabolites, 2025, 15(5): 285. doi: 10.3390/metabo15050285 [10] Akiso M, Ameka M, Naidoo K, et al. Metabolic and mitochondrial dysregulation in CD4+ T cells from HIV-positive women on combination anti-retroviral therapy[J]. PLoS One, 2023, 18(10): e0286436. doi: 10.1371/journal.pone.0286436 [11] Bayarsaikhan S, Jagdagsuren D, Gunchin B, et al. Survival, CD4 T lymphocyte count recovery and immune reconstitution pattern during the first-line combination antiretroviral therapy in patients with HIV-1 infection in Mongolia[J]. PLOS ONE, 2021, 16(3): e0247929. doi: 10.1371/journal.pone.0247929 [12] Shu Y, Zhang M, Li J, et al. Trajectories of CD4 T-cell count, CD8 T-cell count, and CD4/CD8 ratio in patients with HIV and long-term virological suppression based on Yunnan HIV cohort[J]. HIV Med, 2025, 26(1): 70-80. doi: 10.1111/hiv.13707 [13] Zhao Y, McGoogan J M, Wu Z. The benefits of immediate ART[J]. J Int Assoc Provid AIDS Care, 2019, 18: 2325958219831714. [14] Wiche Salinas T R, Zhang Y, Gosselin A, et al. Alterations in Th17 cells and non-classical monocytes as a signature of subclinical coronary artery atherosclerosis during ART-treated HIV-1 infection[J]. Cells, 2024, 13(2): 157. doi: 10.3390/cells13020157 [15] Lee J, Lathia J D. Help! male hormones dampen CD4+ T-cell help in cancer[J]. Cancer Immunol Res, 2026, 14(7): 1052-1053. doi: 10.1158/2326-6066.CIR-26-0513 [16] 杨鸿鑫, 赵志峰, 袁雅冬. 《中国艾滋病诊疗指南(2024版)》专家解读[J]. 疑难病杂志, 2025, 24(12): 1409-1414. doi: 10.3969/j.issn.1671-6450.2025.12.001 [17] O'Neil T R, Hu K, Truong N R, et al. The role of tissue resident memory CD4 T cells in herpes simplex viral and HIV Infection[J]. Viruses, 2021, 13(3): 359. doi: 10.3390/v13030359 [18] Ling L, De C, Spagnuolo R A, et al. Transient CD4+ T cell depletion during suppressive ART reduces the HIV reservoir in humanized mice[J]. PLOS Pathog, 2023, 19(12): e1011824. doi: 10.1371/journal.ppat.1011824 [19] Ludgate S, Connolly S P, Fennell D, et al. Graves' disease associated with HIV disease and late immune reconstitution inflammatory syndrome following the initiation of antiretroviral therapy[J]. Endocrinol Diabetes Metab Case Rep, 2021, 2021: 21-0094. [20] Brazier E, Tymejczyk O, Zaniewski E, et al. Effects of national adoption of treat-all guidelines on pre-antiretroviral therapy (art) cd4 testing and viral load monitoring after art initiation: a regression discontinuity analysis[J]. Clin Infect Dis, 2021, 73(6): e1273-e1281. doi: 10.1093/cid/ciab222 [21] Singh H, Samani D, Aggarwal S. TLR7 polymorphism (rs179008 and rs179009) in HIV-infected individual naïve to ART[J]. Mediators Inflamm, 2020, 2020: 6702169. doi: 10.1155/2020/6702169 [22] Scherpenisse M, Kootstra N A, Bakker M, et al. Cell-associated HIV-1 unspliced-to-multiply-spliced RNA ratio at 12 weeks of ART predicts immune reconstitution on therapy[J]. mBio, 2021, 12(2): e00099-e00021. doi: 10.1128/mbio.00099-21 [23] Yaseen M M, Abuharfeil N M, Darmani H. MDSC expansion during HIV infection: regulators, ART and immune reconstitution[J]. Genes Immun, 2024, 25(3): 242-253. doi: 10.1038/s41435-024-00272-9 [24] Guedes M C S, Carvalho-Silva W H V, Andrade-Santos J L, et al. HIV-induced thymic insufficiency and aging-related immunosenescence on immune reconstitution in ART-treated patients[J]. Vaccines, 2024, 12(6): 612. doi: 10.3390/vaccines12060612 [25] Yang H, Liu Q, Wu Y, et al. Paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome in initiating ART among HIV-infected patients in China-risk factors and management[J]. BMC Infect Dis, 2024, 24(1): 5. doi: 10.1186/s12879-023-08897-3 -
下载: